参考文献/References:
［1］ Global Burden of Disease Cancer Collaboration， Fitzmaurice C， Allen C， et al. Global， regional， and national cancer incidence， mortality， years of life lost， years lived with disability， and disability- adjusted life- years for 32 cancer groups， 1990 to 2015：a systematic analysis for the global burden of disease study［J］. JAMA Oncol， 2017， 3: 524- 548.
［2］ Chen W， Zheng R， Baade PD， et al. Cancer statistics in China， 2015［J］. CA Cancer J Clin， 2016， 66: 115- 132.
［3］ 韩苏军，张思维，陈万青，等． 中国前列腺癌发病现状和流行趋势分析［J］． 临床肿瘤学杂志， 2013， 18：330- 334．
［4］ Siegel RL， Miller KD， Jemal A. Cancer statistics， 2018［J］. CA Cancer J Clin， 2018， 68: 7- 30.
［5］ Miller KD， Siegel RL， Lin CC， et al. Cancer treatment and survivorship statistics， 2016［J］. CA Cancer J Clin， 2016， 66: 271- 289.
［6］ 宋国平，程英升． MR多序列成像对前列腺癌穿刺活检及重复活检的指导价值［J］． 介入放射学杂志， 2013， 22：605- 609．
［7］ Bill- Axelson A， Holmberg L， Garmo H， et al. Radical prostatectomy or watchful waiting in early prostate cancer［J］. N Engl J Med， 2014， 370: 932- 942.
［8］ Hambrock T， Somford DM， Huisman HJ， et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and gleason grade in peripheral zone prostate cancer［J］. Radiology， 2011， 259: 453- 461.
［9］ Woo S， Suh CH， Kim SY， et al. Diagnostic performance of prostate imaging reporting and data system version 2 for detection of prostate cancer: a systematic review and diagnostic meta- analysis［J］. Eur Urol， 2017， 72: 177- 188.
［10］ Dola EF， Nakhla OL， Genidi EA. Assessing the validity of Prostate Imaging Reporting and Data System version 2（PI- RADS v2） scoring system in diagnosis of peripheral zone prostate cancer ［J］. Eur J Radiol Open， 2017， 4:19- 26.
［11］ Siddiqui MM， Rais- Bahrami S， Turkbey B， et al. Comparison of MR/ultrasound fusion- guided biopsy with ultrasound- guided biopsy for the diagnosis of prostate cancer［J］. JAMA， 2015， 313: 390- 397.
［12］ Kitajima K， Murphy RC， Nathan MA， et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11CCholine PET/CT with pelvic multiparametric MR imaging with endorectal coil［J］. J Nucl Med， 2014， 55: 223- 232.
［13］ Reske SN， Blumstein NM， Glatting G. 11Ccholine PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy［J］. Eur J Nucl Med Mol Imaging， 2008， 35: 9- 17.
［14］ Parker WP， Davis BJ， Park SS， et al. Identification of site- specific recurrence following primary radiation therapy for prostate cancer using C- 11choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease［J］. Eur Urol， 2017， 71: 340- 348.
［15］ Perera M， Papa N， Christidis D， et al. Sensitivity， specificity， and predictors of positive Ga- 68- prostate- specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta- analysis［J］. Eur Urol， 2016， 70: 926- 937.
［16］ Afshar- Oromieh A， Sattler LP， Mier W， et al. The clinical impact of additional late PET/CT imaging with Ga- 68- PSMA- 11 （HBED- CC） in the diagnosis of prostate cancer［J］. J Nucl Med， 2017， 58: 750- 755.
［17］ Henninger M， Maurer T， Hacker C， et al. 68Ga- PSMA PET/MR showing intense PSMA uptake in nodular fasciitis mimicking prostate cancer metastasis［J］. Clin Nucl Med， 2016， 41: e443- e444.
［18］ Kasivisvanathan V， Rannikko AS， Borghi M， et al. MRI- targeted or standard biopsy for prostate- cancer diagnosis［J］. N Engl J Med， 2018， 378: 1767- 1777.
［19］ Haffner J， Lemaitre L， Puech P， et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging- targeted and systematic biopsy for significant prostate cancer detection［J］. BJU Int， 2011， 108: E171- E178.
［20］ Valerio M， McCartan N， Freeman A， et al. Visually directed vs. software- based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer［J］. Urol Oncol， 2015， 33: 424.e9- 424e16.
［21］ Mozer P， Roupret M， Le Cossec C， et al. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography- guided biopsies for the diagnosis of localised prostate cancer［J］. BJU Int， 2015， 115: 50- 57.
［22］ Meng X， Rosenkrantz AB， Mendhiratta N， et al. Relationship between prebiopsy multiparametric magnetic resonance imaging （MRI）， biopsy indication， and MRI- ultrasound fusion- targeted prostate biopsy outcomes［J］. Eur Urol， 2016， 69: 512- 517.
［23］ Sonn GA， Chang E， Natarajan S， et al. Value of targeted prostate biopsy using magnetic resonance- ultrasound fusion in men with prior negative biopsy and elevated prostate- specific antigen［J］. Eur Urol， 2014， 65: 809- 815.
［24］ Hoeks CM， Schouten MG， Bomers JG， et al. Three- tesla magnetic resonance- guided prostate biopsy in men with increased prostate- specific antigen and repeated， negative， random， systematic， transrectal ultrasound biopsies: detection of clinically significant prostate cancers［J］. Eur Urol， 2012， 62: 902- 909.
［25］ Filson CP， Natarajan S， Margolis DJ， et al. Prostate cancer detection with magnetic resonance- ultrasound fusion biopsy: the role of systematic and targeted biopsies［J］. Cancer， 2016， 122: 884- 892.
［26］ Delongchamps NB， Lefèvre A， Bouazza N， et al. Detection of significant prostate cancer with magnetic resonance targeted biopsie: should transrectal ultrasound- magnetic resonance imaging fusion guided biopsies alone be a standard of care?［J］. J Urol， 2015， 193: 1198- 1204.
［27］ Mertan FV， Greer MD， Shih JH， et al. Prospective evaluation of the prostate imaging reporting and data system version 2 for prostate cancer detection［J］. J Urol， 2016， 196: 690- 696.
［28］ Hambrock T， Hoeks C， Hulsbergen- van de Kaa C， et al. Prospective assessment of prostate cancer aggressiveness using 3- T diffusion- weighted magnetic resonance imaging- guided biopsies versus a systematic 10- core transrectal ultrasound prostate biopsy cohort［J］. Eur Urol， 2012， 61: 177- 184.
［29］ Parker C， Sydes MR， Kynaston H， et al. Re: Sanoj Punnen, Matthew R. Cooperberg, Authony V.D’Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah，Nazareno Suardi，Cesare Cozzarini，et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long- term survival analysis. Eur Urol 2013； 63: 998- 1008［J］. Eur Urol， 2013， 64: e102.
［30］ Passoni NM， Polascik TJ. How to select the right patients for focal therapy of prostate cancer?［J］. Curr Opin Urol， 2014， 24: 203- 208.
［31］ van den Bosch MA， Josan S， Bouley DM， et al. MR imaging- guided percutaneous cryoablation of the prostate in an animal model: in vivo imaging of cryoablation- induced tissue necrosis with immediate histopathologic correlation［J］. J Vasc Interv Radiol， 2009， 20: 252- 258.
［32］ 杨红彩，郭 志，司同国，等． 去势抵抗性前列腺癌患者冷冻消融治疗后中性粒细胞与淋巴细胞比值变化的意义［J］． 介入放射学杂志， 2017， 26： 237- 242．
［33］ 王莹娟， 司同国， 杨雪玲， 等. 冷冻消融联合内分泌治疗T3期转移性前列腺癌的临床疗效及预后分析［J］. 介入放射学杂志， 2018， 27: 327- 333.
［34］ Woodrum DA， Kawashima A， Karnes RJ， et al. Magnetic resonance imaging- guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience［J］. Urology， 2013， 82: 870- 875.
［35］ Stafford RJ， Shetty A， Elliott AM， et al. Magnetic resonance guided， focal laser induced interstitial thermal therapy in a canine prostate model［J］. J Urol， 2010， 184: 1514- 1520.
［36］ Woodrum DA， Gorny KR， Mynderse LA， et al. Feasibility of 3. 0T magnetic resonance imaging- guided laser ablation of a cadaveric prostate［J］. Urology， 2010， 75: 1- 6.
［37］ Lee T， Mendhiratta N， Sperling D， et al. Focal laser ablation for localized prostate cancer: principles，clinical trials，and our initial experience［J］. Rev Urol， 2014， 16: 55.
［38］ Raz O， Haider MA， Davidson SR， et al. Corrigendum to“Real- time magnetic resonance imaging- guided focal laser therapy in patients with low- risk prostate cancer”［Eur Urol 2010， 58:173- 77］［J］. Eur Urol， 2010， 58: 473.
［39］ Woodrum DA， Mynderse LA， Gorny KR， et al. 3.0T MR- guided laser ablation of a prostate cancer recurrence in the postsurgical prostate bed［J］. J Vasc Interv Radiol， 2011， 22: 929- 934.
［40］ 王中领，张贵祥． MR引导下聚焦超声刀的临床应用及技术进展［J］. 国际医学放射学杂志， 2017， 40： 565- 569．
［41］ Favazza CP， Gorny KR， King DM， et al. An investigation of the effects from a urethral warming system on temperature distributions during cryoablation treatment of the prostate: a phantom study［J］. Cryobiology， 2014， 69: 128- 133.
［42］ Kuroda K. MR techniques for guiding high- intensity focused ultrasound（HIFU） treatments［J］. J Magn Reson Imaging， 2018， 47: 316- 331.
［43］ Soher BJ， Wyatt C， Reeder SB， et al. Noninvasive temperature mapping with MRI using chemical shift water- fat separation［J］. Magn Reson Med， 2010， 63: 1238- 1246.
［44］ Woodrum DA， Kawashima A， Gorny KR， et al. Prostate cancer: state of the art imaging and focal treatment［J］. Clin Radiol， 2017， 72: 665- 679.
相似文献/References:
[1]杨玉媚,杜端明,陈继冰,等.不可逆电穿孔消融治疗前列腺癌5例 [J].介入放射学杂志,2018,27(09):854.
YANG Yumei,DU Duanming,CHEN Jibing,et al.Irreversible electroporation ablation for prostate cancer： five patients report[J].journal interventional radiology,2018,27(11):854.
[2]邢朋毅,阳青松,王立鹏,等.基于MRI的前列腺癌局灶治疗研究现状[J].介入放射学杂志,2019,28(11):1113.
XING Pengyi,YANG Qingsong,WANG Lipeng,et al. Current research status of MRI-based focal treatment of prostate cancer[J].journal interventional radiology,2019,28(11):1113.